Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACE + Lenvatinib + PD-1 Inhibitor for Ruptured HCC
NCT06740370Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Dec 2024
- Primary completion
- Dec 2025
- Modality
- Immune Checkpoint Inhibitors, Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of lenvatinib, tislelizumab, sintilimab and camrelizumab in hepatocellular carcinoma (HCC), sponsored by Sun Yat-sen University. Primary endpoint: Progression-Free-Survival at 12 months. Started Dec 2024; status: recruiting.
02
Drugs
lenvatinibtislelizumabsintilimabcamrelizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06740370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06740370.